How big is the syndromic multiplex diagnostics market?

The global syndromic multiplex diagnostics market size was estimated at USD 2.92 billion in 2024 and is expected to reach USD 3.02 billion in 2025.

What is the syndromic multiplex diagnostics market growth?

The global syndromic multiplex diagnostics market is expected to grow at a compound annual growth rate of 3.91% from 2025 to 2030 to reach USD 3.66 billion by 2030.

Which segment accounted for the largest syndromic multiplex diagnostics market share?

North America dominated the syndromic multiplex diagnostics market with a share of 41.85% in 2024. This is attributable to the presence of key market players, evolving regulatory landscape, developed healthcare infrastructure, and increasing prevalence of various infectious diseases.

Who are the key players in syndromic multiplex diagnostics market?

Some key players operating in the syndromic multiplex diagnostics market include Abbott Laboratories; Thermo Fisher Scientific, Inc.; F. Hoffmann-La Roche Ltd; Qiagen; bioMérieux; DiaSorin S.p.A (Luminex Corporation); Hologic, Inc.; Becton, Dickinson and Company (BD); Applied BioCode; QIAGEN

What are the factors driving the syndromic multiplex diagnostics market?

Key factors that are driving the market growth include the rising demand for rapid, and accurate diagnostics, advancements in diagnostics technologies, and rising prevalence of infectious diseases globally. Increasing incidences of infectious diseases such as respiratory infections, gastrointestinal diseases, and STIs among others have fueled the demand for syndromic testing.